We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+0.68%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$10.2B
AUM Growth
-$819M
Cap. Flow
-$1.84B
Cap. Flow %
-18.03%
Top 10 Hldgs %
83.92%
Holding
140
New
7
Increased
13
Reduced
18
Closed
7

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$96.9M
2
ONC
BeOne Medicines Ltd
ONC
+$55.3M
3
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$38.3M
4
AKAO
Achaogen Inc
AKAO
+$30.7M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$16.8M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$773M
2
EXEL icon
Exelixis
EXEL
+$27.8M
3
TGTX icon
TG Therapeutics
TGTX
+$15.5M
4
ARWR icon
Arrowhead Research
ARWR
+$13.6M
5
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.85%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CFRX
51
DELISTED
ContraFect Corporation
CFRX
$7.08M 0.07%
5,057
– –
IMGN
52
DELISTED
Immunogen Inc
IMGN
$6.15M 0.06%
3,015,353
– –
DMTX
53
DELISTED
Dimension Therapeutics, Inc
DMTX
$5.45M 0.05%
1,251,881
– –
AGIO icon
54
Agios Pharmaceuticals
AGIO
$1.98B
$5.37M 0.05%
128,666
-79,249
-38% -$4.16M
CPRX
55
DELISTED
Catalyst Pharmaceutical
CPRX
$5.36M 0.05%
5,102,153
– –
INSM icon
56
Insmed
INSM
$27.5B
$5.29M 0.05%
400,000
– –
ARCT icon
57
Arcturus Therapeutics
ARCT
$382M
$4.91M 0.05%
333,766
– –
RIGL icon
58
Rigel Pharmaceuticals
RIGL
$857M
$4.8M 0.05%
+201,888
New +$5.78M
BIIB icon
59
Biogen
BIIB
$32B
$4.68M 0.05%
+16,500
New +$4.89M
GNMX
60
DELISTED
Aevi Genomic Medicine Inc
GNMX
$4.56M 0.04%
880,539
– –
ALDR
61
DELISTED
Alder Biopharmaceuticals
ALDR
$4.52M 0.04%
217,328
– –
LOXO
62
DELISTED
Loxo Oncology, Inc
LOXO
$4.42M 0.04%
137,735
– –
STML
63
DELISTED
Stemline Therapeutics, Inc.
STML
$3.57M 0.04%
333,497
– –
RARE icon
64
Ultragenyx Pharmaceutical
RARE
$2.55B
$3.52M 0.03%
50,000
-50,000
-50% -$3.55M
AKTX
65
Akari Therapeutics
AKTX
$15.3M
$3.5M 0.03%
621
– –
NERV icon
66
Minerva Neurosciences
NERV
$231M
$3.04M 0.03%
32,351
– –
ASMB icon
67
Assembly Biosciences
ASMB
$700M
$3.04M 0.03%
20,833
– –
RXDX
68
DELISTED
Ignyta, Inc.
RXDX
$3.03M 0.03%
571,000
– –
RNAC icon
69
Cartesian Therapeutics
RNAC
$304M
$3.01M 0.03%
5,857
-108
-2% -$63.1K
NTRA icon
70
Natera
NTRA
$47.9B
$2.92M 0.03%
249,269
-200,731
-45% -$2.21M
ADMS
71
DELISTED
Adamas Pharmaceuticals
ADMS
$2.92M 0.03%
172,630
– –
EPZM
72
DELISTED
Epizyme, Inc
EPZM
$2.81M 0.03%
232,481
– –
IONS icon
73
Ionis Pharmaceuticals
IONS
$9.93B
$2.73M 0.03%
57,140
– –
RARX
74
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$2.7M 0.03%
+177,952
New +$2.42M
VIRX
75
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.69M 0.03%
21,190
– –
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2016 Portfolio in Review

As of Q4 2016, Julian Baker held 140 positions worth $10.2B, down 7.4% from $11B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Julian Baker withdrew a net $1.84B in Q4 2016, closing 7 positions and reducing 18 holdings. Its most notable exit was TG Therapeutics, an estimated $15.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 88% a quarter earlier, followed by Technology.

Against the trend, Julian Baker opened a new position in AveXis, Inc. Common Stock worth $15M.

  • Julian Baker's largest Q4 2016 buy was AveXis, Inc. Common Stock: 315,300 shares worth $15M.
  • Julian Baker added most to Seagen Inc. Common Stock in Q4 2016, an estimated $96.9M increase.
  • Julian Baker's biggest Q4 2016 reduction was AbbVie, cutting an estimated $773M.
  • Julian Baker fully exited TG Therapeutics in Q4 2016, selling an estimated $15.5M.
  • Julian Baker's ten largest holdings make up 84% of its $10.2B portfolio in Q4 2016.
  • Julian Baker opened 7 new positions and closed 7 in Q4 2016.
  • Julian Baker's portfolio value fell 7.4% quarter-over-quarter to $10.2B.

Based on Baker Bros. Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.